Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: WTDEC who wrote (21389)	5/25/1998 10:03:00 PM
From: Flagrante Delictu	Read Replies (1) \| Respond to of 32384

Walter, Nanovectors are based on nanoerythrosomes, microspheres produced from red blood cells. They can be used as carriers for therapeutic molecules or genes to cancer cells or other cellular targets. SRGN designs & develops fusion proteins which consist of 3 parts, each with a specific function. The first part binds to the cell surface (the receptor binding domain or "probe"); the second facilitates insertion of the fusion protein (IYWPTE) into the cell membrane *the transmembrane domain or "syringe"); and the third eliminates the target cell (IYWPTE)(toxic domain). These 3 parts can be employed separately, or joined to other entities through molecular engineering techniques. The result of this combination is a fusion protein. DiagnoCure's licensing agreement with SRGN covers fusion proteins composed of the "syringe" & "probe" portions of SRGN's fision proteins.DiagnoCure plans to exploit this technology & to fuse, among other things, various proprietary monoclonal antibodies to replace the "probe". A monoclonal antibody is a protein capable of recognizing an antigen or specific receptor, and only that receptor, present on the surface of a cancer cell. It is therefore a very high precision "probe", DiagnoCure plans to insert these new fusion proteins into the membrane of its' nanoerythrosomes (IYWPTE). The "syringe" portion should facilitate this operation. Nanoerythrosomes, bound in this way to monoclonal antibodies, would then become highly selective nanovectors capable of transporting their therapeutic contents to targetted cancer cells without affecting healthy ones.